Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

What It Covers

Dr. Matthew Johnson explains how psychedelics like psilocybin and MDMA work through serotonin receptors to alter sense of self, enabling therapeutic breakthroughs in depression, PTSD, and addiction through carefully guided clinical sessions.

Key Questions Answered

• •Therapeutic mechanism: Psychedelics dissolve rigid self-models by profoundly altering reality perception during sessions, allowing patients to experience agency differently—smokers realize they can simply decide to quit, depressed patients recognize they control their suffering beyond medical treatment.
• •Session protocol: Clinical psilocybin therapy involves cardiovascular and psychiatric screening to exclude schizophrenia and bipolar disorder, followed by preparation sessions building therapeutic rapport with guides, then 20-30mg doses administered in safe environments encouraging complete surrender to the experience.
• •Bad trip gateway: Approximately one-third of patients experience intense anxiety or fear of losing sanity during high-dose sessions, but this reality-shattering moment serves as the gateway to transcendental experiences when patients surrender rather than resist the dissolution of self.
• •Microdosing evidence: Peer-reviewed studies show no cognitive enhancement or sustained mood improvement from microdosing psychedelics. Some research indicates slight impairment in time perception and cognition, contradicting popular claims about productivity and creativity benefits from sub-perceptual doses.